Lv4
552 积分 2022-09-19 加入
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers
15天前
已完结
Erythropoietin-Producing Hepatocellular Receptors A: Ephrin A1, Ephrin A2 and Ephrin A3
16天前
已完结
[Expression and clinical significance of Ephrin-A1 in primary hepatocellular carcinoma]
16天前
已关闭
Ephs and ephrins in cancer: Ephrin-A1 signalling
16天前
已完结
Eph receptors and ephrins in cancer progression
16天前
已完结
An integrated analysis of single-cell and bulk transcriptomics reveals EFNA1 as a novel prognostic biomarker for cervical cancer
17天前
已完结
The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors
17天前
已完结
Therapeutic potential of cis-targeting bispecific antibodies
18天前
已完结
Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers
23天前
已完结
Tumour-agnostic kinase inhibitors
1个月前
已完结
皖公网安备34019202002308
